Welcome to our dedicated page for HNSA news (Ticker: HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.
Hansa Biopharma AB (HNSA) news covers developments at a commercial-stage biopharmaceutical company focused on rare immunological conditions. Based in Lund, Sweden, with operations in Europe and the U.S., Hansa Biopharma reports on progress across its proprietary IgG-cleaving enzyme technology platform, including transplantation, autoimmune diseases and gene therapy applications.
News for HNSA frequently highlights clinical and regulatory milestones for imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy that has been shown to enable kidney transplantation in highly sensitized patients. Updates include data from the pivotal U.S. Phase 3 ConfIdeS trial in kidney transplantation, long-term follow-up analyses of imlifidase-enabled transplants, and the company’s submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for desensitization of highly sensitized adult patients undergoing deceased donor kidney transplantation.
Investors following HNSA news can also expect information on IDEFIRIX product performance in approved markets, progress of next-generation asset HNSA-5487, and updates from gene therapy-related studies where imlifidase is used to reduce anti-AAV antibodies. Company announcements regularly cover participation in scientific congresses, virtual scientific and investor events, and corporate developments such as executive appointments and financing transactions.
This news feed provides a centralized view of Hansa Biopharma’s disclosures on its clinical programs, regulatory interactions, commercial activities and strategic initiatives linked to its IgG-cleaving enzyme platform. Readers interested in HNSA stock and the company’s role in rare immunological conditions can use this page to monitor key trial readouts, regulatory milestones and other material company updates over time.
Hansa Biopharma (HNSA) has completed the randomization phase in its pivotal Phase 3 US ConfIdeS trial. This trial evaluates the efficacy of imlifidase in kidney transplantation for highly sensitized patients. The trial involves 64 patients and is conducted across 24 US sites. The primary endpoint is kidney graft function at 12 months, measured by eGFR. Data from this trial will support a Biologic License Application (BLA) to the FDA, expected in H2 2025. Imlifidase, already conditionally approved in Europe under IDEFIRIX® for similar indications, is also being explored for autoimmune diseases and as a pre-treatment in gene therapy.
Hansa Biopharma (NASDAQ: HNSA) announced it will present data on its antibody-cleaving enzyme imlifidase at the 2024 American Transplant Congress (ATC). Imlifidase targets IgG and inhibits the IgG-mediated immune response, aiding highly sensitized kidney transplant patients. Key presentations include the reestablishment of COVID-specific IgG antibodies and long-term clinical outcomes of imlifidase. Hansa has conditional European approval for imlifidase under the name IDEFIRIX® and plans to submit a Biologic License Application to the US FDA in 2025. The enzyme is also being studied for pre-treating gene therapy in rare diseases and certain autoimmune conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.